Abstract
In the present study, novel proniosomal gel of ursolic acid was prepared by encapsulation of the drug in a mixture of span 60, cholesterol and alcohol by coacervation phase separation method to overcome the bioavailability problem of this potential biologically active compound. The formulated system was characterized for size, drug entrapment, in‑vitro drug release studies and in‑vivo anti‑inflammatory effect through animal model. In‑vitro release data of ursolic acid from proniosomal gel revealed a time dependent near linear relationship. Entrapment efficiency of the formulated gel was found > 90% and total % cumulative release of ursolic acid satisfactory as 60.8% after 24 h. Release pattern was also found almost constant. In‑vivo evaluation revealed that the developed formulation exhibited significant anti‑inflammatory value (P < 0.05) in carrageenan induced rat paw edema model and was found quite comparable with the standard diclofenac gel (voveran gel) in terms of % inhibition of edema. Key words: Non‑steroidal anti‑inflammatory drugs, proniosomes, topical drug delivery, ursolic acid
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
